Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood

• Publication date

  2005-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2005-03-1072PMID 16131573PMCID PMC1895250
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

  2004cited by this paper
• Heteroclitic CD33 Peptide With Enhanced Anti-Acute Myeloid Leukemic Immunogenicity

  2004cited by this paper
• Establishment of a pluripotent preleukaemic stem cell line by expression of the AML1‐ETO fusion protein in Notch1‐immortalized HSCN1cl10 cells

  2004cited by this paper
• Hematopoietic stem cells expressing the myeloid lysozyme gene retain long-term, multilineage repopulation potential.

  2003cited by this paper
• A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

  2003cited by this paper
• Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?

  2003cited by this paper
• Priming the hematopoietic pump.

  2003cited by this paper
• Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis.

  2003cited by this paper
• Myeloid-lymphoid initiating cells (ML-IC) are highly enriched in the rhodamine-c-kit(+)CD33(-)CD38(-) fraction of umbilical cord CD34(+) cells.

  2002cited by this paper
• A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.

  2002cited by this paper
• Targeted α particle immunotherapy for myeloid leukemia

  2002cited by this paper
• Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling.

  2002cited by this paper
• Targeted alpha particle immunotherapy for myeloid leukemia.

  2002cited by this paper
• Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

  2001cited by this paper
• Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.

  2001cited by this paper
• Distinct classes of human stem cells that differ in proliferative and self-renewal potential

  2001cited by this paper
• Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2.

  2000cited by this paper
• The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

  2000cited by this paper
• Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice.

  1999cited by this paper
• Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells.

  1999cited by this paper
• Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

  1997cited by this paper
• Multilineage gene expression precedes commitment in the hemopoietic system.

  1997cited by this paper
• Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy

  1996cited by this paper
• Expression of CD33, CD38, and HLA-DR on CD34+ human fetal liver progenitors with a high proliferative potential.

  1994cited by this paper
• Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow cells.

  1994cited by this paper
• A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

  1994cited by this paper
• Human hematopoietic precursors in long-term culture: single CD34+ cells that lack detectable T cell, B cell, and myeloid cell antigens produce multiple colony-forming cells when cultured with marrow stromal cells

  1990cited by this paper
• Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties

  1989cited by this paper
• The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors.

  1986cited by this paper
• A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells.

  1984cited by this paper

• Targeted Therapy for CD13‐Overexpressing Triple‐Negative Breast Cancers Using Apoptosis‐Inducing Protein Cage Nanoparticles

  2026cites this paper
• Implementation of Natural Products and Derivatives in Acute Myeloid Leukemia Management: Current Treatments, Clinical Trials and Future Directions

  2026cites this paper
• Single cell transcriptomics derived combinatorial markers distinguished leukemic stem cells from hematopoietic stem cells in acute myeloid leukemia.

  2026cites this paper
• JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025

  2025cites this paper
• Optimal Chimeric Antigen Receptor (CAR)-mRNA for Transient CAR T Cell Generation

  2025cites this paper
• Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting

  2025cites this paper
• Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction.

  2025cites this paper
• Systematic pan-cancer analysis of IL3RA carcinogenesis in human tumors, combined with bioinformatics analysis

  2025cites this paper
• Dual nanobody-redirected and Bi-specific CD13/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs

  2025cites this paper
• Disease characteristics and outcomes of Croatian pediatric patients with acute lymphoblastic leukemia: pretreatment immunophenotypic predictors of high bone marrow minimal residual disease on day 15 of treatment

  2025cites this paper
• Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia

  2025cites this paper
• Flow cytometry evaluation of acute myeloid leukemia minimal residual disease based on an understanding of the normal maturation patterns in the blast compartments.

  2025cites this paper
• Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy

  2025cites this paper
• CAR T cell therapy for treatment of Acute Myeloid Leukemia, Advances and Outcomes.

  2025cites this paper
• Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

  2025cites this paper
• Novel approaches to CAR T cell target identification in acute myeloid leukemia.

  2025cites this paper
• Clec12a is required for the pathogenesis of NUP98::NSD1 AML

  2025cites this paper
• Strategies to enhance anti-leukaemia immunotherapy.

  2025cites this paper
• Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalities

  2025cites this paper
• Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy

  2025cites this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cites this paper
• Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities

  2025cites this paper
• Norchelerythrine from Corydalis incisa (Thunb.) Pers. promotes differentiation and apoptosis by activating DNA damage response in acute myeloid leukemia

  2025cites this paper
• Preclinical targeting of leukemia-initiating cells in the development future biologics for acute myeloid leukemia

  2025cites this paper
• Recent advances in CAR‐T cell therapy for acute myeloid leukaemia

  2024cites this paper
• IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells

  2024cites this paper
• Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile

  2024cites this paper
• Emerging CART Therapies for Pediatric Acute Myeloid Leukemia

  2024cites this paper
• Honing CAR T cells to tackle acute myeloid leukemia.

  2024cites this paper
• Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations

  2024cites this paper
• CD13-targeting and TRAIL-displaying protein nanoparticles effectively induce apoptotic cell death of acute myeloid leukemia, prolonging survival in mouse models

  2024cites this paper
• Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy

  2024cites this paper
• Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia.

  2024cites this paper
• Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML

  2024cites this paper
• EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia

  2024cites this paper
• Immunophenotypic features of early haematopoietic and leukaemia stem cells

  2024cites this paper
• The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia

  2024cites this paper
• Impact of scFv on functionality and safety of third generation CD123 CAR T cells.

  2024cites this paper
• Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells

  2023cites this paper
• Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development

  2023cites this paper
• Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

  2023cites this paper
• Cooperative CAR targeting to selectively eliminate AML and minimize escape.

  2023cites this paper
• Bispecific Antibodies in Hematological Malignancies: A Scoping Review

  2023cites this paper
• Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances

  2023cites this paper
• Tetraspanin CD81 promotes leukemia stem cell function and represents a new therapeutic vulnerability in acute myeloid leukemia

  2023cites this paper
• Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression

  2023cites this paper
• Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?

  2023cites this paper
• Molecular Mechanisms in Murine Syngeneic Leukemia Stem Cells

  2023cites this paper
• A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges

  2023cites this paper
• Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia

  2023cites this paper
• PARP10 is highly expressed and associated with inferior outcomes in acute myeloid leukemia

  2023cites this paper
• Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution

  2023cites this paper
• Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia

  2022cites this paper
• Deciphering the Non-Coding RNA Landscape of Pediatric Acute Myeloid Leukemia

  2022cites this paper
• Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL‐2 expression by cytogenetic subgroups

  2022cites this paper
• Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication

  2022cites this paper
• Emerging CAR T Cell Strategies for the Treatment of AML

  2022cites this paper
• Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells

  2022cites this paper
• Gemtuzumab Ozogamicin Treatment Results in Decreased Proliferation and Differentiation of Human Megakaryocytes but Does Not Inhibit Mature Platelet Function

  2022cites this paper
• Chimeric antigen receptor T-cell therapy for T-ALL and AML

  2022cites this paper
• Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)

  2022cites this paper
• IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML

  2022cites this paper
• Augmented Expression of the IL3RA/CD123 Gene in MLL/KMT2A-Rearranged Pediatric AML and Infant ALL

  2022cites this paper
• Markers for human haematopoietic stem cells: The disconnect between an identification marker and its function

  2022cites this paper
• Hyper-radiosensitivity affects low-dose acute myeloid leukemia incidence in a mathematical model

  2022cites this paper
• Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications

  2022cites this paper
• Proteomic Profiling Identifies Specific Leukemic Stem Cell-Associated Protein Expression Patterns in Pediatric AML Patients

  2022cites this paper
• Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.

  2022cites this paper
• Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications

  2022influential citation
• CAR‐T‐Zellen auf dem Weg zur praktischen Anwendung in der dermatologischen Onkologie

  2021cites this paper
• CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity.

  2021cites this paper
• Driving CAR T cells towards dermatologic oncology

  2021cites this paper
• Emerging Immunotherapy for Acute Myeloid Leukemia

  2021cites this paper
• Multi-modal profiling of human fetal liver hematopoietic stem cells reveals the molecular signature of engraftment

  2021cites this paper
• CD123 Is Consistently Expressed on NPM1-Mutated AML Cells

  2021cites this paper
• SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells

  2021cites this paper
• Genome editing in large animal models.

  2021cites this paper
• NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity

  2021influential citation
• A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

  2021cites this paper
• PU.1 Mimic Synthetic Peptides Selectively Bind with GATA-1 and Allow c-Jun PU.1 Binding to Enhance Myelopoiesis

  2021cites this paper
• Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML

  2021cites this paper
• A modular and controllable T cell therapy platform for acute myeloid leukemia

  2021cites this paper
• Asymmetric organelle inheritance predicts human blood stem cell fate.

  2021cites this paper
• Sialic acid‐binding immunoglobulin‐like lectin (Sigelac)‐15 is a rapidly internalised cell‐surface antigen expressed by acute myeloid leukaemia cells

  2021cites this paper
• Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy

  2021cites this paper
• Chronic myeloid leukemia stem cells: targeting therapeutic implications

  2021cites this paper
• Redirecting the Immune Microenvironment in Acute Myeloid Leukemia

  2021cites this paper
• Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia

  2021influential citation
• Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia

  2021cites this paper
• An increase in DNA G-quadruplex formation in acute myelocytic leukemia is detected by a supramolecular probe.

  2021cites this paper
• Combination of FLT3-ITD allelic ratio, NPM1 mutation, and immunophenotypic markers to modulate outcome prediction in normal karyotype AML undergoing hematopoietic stem cell transplantation.

  2020cites this paper
• LILRB4-targeting Antibody–Drug Conjugates for the Treatment of Acute Myeloid Leukemia

  2020cites this paper
• A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML.

  2020cites this paper
• Targeting mitochondrial respiration for the treatment of acute myeloid leukemia.

  2020cites this paper
• A general view of CD33+ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy

  2020cites this paper
• CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy.

  2020cites this paper
• CD123 as a Therapeutic Target Against Malignant Stem Cells.

  2020cites this paper
• Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia

  2020cites this paper
• ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

  2020cites this paper
• Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia.

  2020cites this paper